Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors — Stella
Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors
Trial locations(8 sites)
United States
Lundquist Inst BioMed at Harbor, Torrance, California
Rocky Mountain Cancer Centers, Denver, Colorado
Johns Hopkins University, Washington D.C., District of Columbia
Duke Clinical Research Institute, Durham, North Carolina
Oncology Hematology Care Inc, Cincinnati, Ohio
Sarah Cannon Research Institute, Nashville, Tennessee